|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1083460118 |
| 003 |
OCoLC |
| 005 |
20231120010338.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
190126s2019 enk ob 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d N$T
|d EBLCP
|d OPELS
|d OCLCF
|d OCLCQ
|d DKU
|d OCLCO
|d OCLCQ
|d S2H
|d OCLCO
|d UX1
|d VT2
|d OCLCA
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBB925709
|2 bnb
|
| 019 |
|
|
|a 1083341395
|a 1083575702
|a 1235828891
|
| 020 |
|
|
|a 9780128167397
|q (electronic bk.)
|
| 020 |
|
|
|a 0128167394
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128164129
|
| 020 |
|
|
|z 0128164123
|
| 035 |
|
|
|a (OCoLC)1083460118
|z (OCoLC)1083341395
|z (OCoLC)1083575702
|z (OCoLC)1235828891
|
| 050 |
|
4 |
|a RC523
|
| 060 |
|
4 |
|a 2019 C-919
|
| 060 |
|
4 |
|a WT 155
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.831
|2 23
|
| 100 |
1 |
|
|a Obulesu, Magisetty.
|
| 245 |
1 |
0 |
|a Alzheimer's disease theranostics /
|c Magisetty Obulesu.
|
| 260 |
|
|
|a London :
|b Elsevier,
|c 2019.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed January 31, 2019)
|
| 505 |
0 |
|
|a Front Cover; Alzheimer's Disease Theranostics; Alzheimer's Disease Theranostics; Copyright; Dedication; Biography; Acknowledgements; Contents; 1 -- Introduction: Alzheimer's Disease Pathology and Therapeutics; ABSTRACT; KEYWORDS; INTRODUCTION; BIOCHEMISTRY; THERANOSTICS; Antibodies; Natural Compounds; Resveratrol; Ginkgo Biloba; Drugs; Nanotechnology; CONCLUSION AND FUTURE PERSPECTIVES; REFERENCES; 2 -- Early Diagnosis of Alzheimer's Disease; ABSTRACT; KEYWORDS; INTRODUCTION; CURCUMIN; CREATIVE DRAWING TECHNIQUE; Imaging Techniques; Positron Emission Tomography Radiotracers; GENETICS
|
| 505 |
8 |
|
|a BIOMARKERSBlood Biomarkers; Protein Biomarkers; MIRNA; GLUCOSE LEVELS; CONCLUSION; REFERENCES; 3 -- Antioxidants in Alzheimer's Therapy; ABSTRACT; KEYWORDS; INTRODUCTION; ANTIOXIDANTS; Plant Extracts; Withanolides; NEUROINFLAMMATION-TARGETED THERAPEUTICS; Antioxidant Enzymes; Limitations; MELATONIN; LIPOIC ACID; NANOTECHNOLOGY; CONCLUSION; REFERENCES; 4 -- Natural Products in the Treatment of Alzheimer's Disease; ABSTRACT; KEYWORDS; INTRODUCTION; FLAVONOIDS; Epigallocatechin-3-Gallate; RESVERATROL; SAIKOSAPONINS; CURCUMIN; CLICK CHEMISTRY; NANOTECHNOLOGY; CHITOSAN; CONCLUSION; REFERENCES
|
| 505 |
8 |
|
|a 5 -- Blood-Brain Barrier-Targeted Nanotechnological AdvancesABSTRACT; KEYWORDS; INTRODUCTION; PHYSIOLOGY; PATHOLOGY; BCSFB; THERAPEUTICS; Matrix Metalloproteinases; Nanoparticles; Gold nanoparticles; Liposomes; Magnetic nanoparticles; CONCLUSIONS AND FUTURE PERSPECTIVES; REFERENCES; 6 -- Gene Therapy: The Cornerstone in the Development of Alzheimer's Disease Therapeutics; ABSTRACT; KEYWORDS; INTRODUCTION; PRESENILIN; STEM CELLS; MICRORNA/CDK5R1; HEAT SHOCK PROTEIN; BECLIN; APOLIPOPROTEIN E; DRUG MECHANISM/GENE MODIFICATION; NEUROINFLAMMATION AND CYTOKINES; CONCLUSION; REFERENCES
|
| 505 |
8 |
|
|a 7 -- Viral Vector Therapeutics Against Alzheimer's DiseaseABSTRACT; KEYWORDS; INTRODUCTION; Viral Vector Therapeutics; Adeno-Associated Viral Vectors; mAbs; Tau; PROGRANULIN; NEPRILYSIN; GENE-BASED IMMUNOTHERAPEUTIC METHODS; CONCLUSION; REFERENCES; 8 -- Mitochondria-Targeted Nanoparticles: A Milestone or a Mirage in the Treatment of Alzheimer's Disease; ABSTRACT; KEYWORDS; INTRODUCTION; Nanoparticles; Flurbiprofen Nanoparticles; Nattokinase Nanoparticles; Intranasal Delivery; Triphenylphosphonium Functionalization; Cerium Oxide Nanoparticles; CONCLUSION; REFERENCES
|
| 505 |
8 |
|
|a 9 -- Nanoparticles: The Double-Edged SwordsABSTRACT; KEYWORDS; INTRODUCTION; Nanotechnology; Polymeric Materials; Carbon Nanotubes; Hydrogels; Tissue Engineering Scaffolds; Delivery Systems for Growth Factors; Delivery Systems for Chelators; DEMERITS OF BIOMATERIALS; CONCLUSIONS AND FUTURE PERSPECTIVES; REFERENCES; 10 -- Alzheimer Therapeutics: Pros and Cons; ABSTRACT; KEYWORDS; INTRODUCTION; Neuroinflammation and Cytokines; Demerits; Antioxidants; Shortcomings; DRUG MECHANISM/GENE MODIFICATION; Neprilysin; Limitations; Nanotechnology; Gold Nanoparticles; Liposomes; Magnetic Nanoparticles
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 650 |
|
0 |
|a Alzheimer's disease.
|
| 650 |
|
2 |
|a Alzheimer Disease
|0 (DNLM)D000544
|
| 650 |
|
2 |
|a Theranostic Nanomedicine
|0 (DNLM)D000068936
|
| 650 |
|
6 |
|a Maladie d'Alzheimer.
|0 (CaQQLa)201-0114128
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Alzheimer's disease
|2 fast
|0 (OCoLC)fst00806532
|
| 776 |
0 |
8 |
|i Print version:
|a Obulesu, Magisetty.
|t Alzheimer's disease theranostics.
|d London : Elsevier, 2019
|z 0128164123
|z 9780128164129
|w (OCoLC)1044835474
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128164129
|z Texto completo
|
